A cohort of tonsil and salivary gland cancer patients who received ipsilateral curative-intent radiotherapy delivered by IMPT or VMAT were reviewed including the treatment plans for dosimetric differences, patient-reported outcomes (PRO) and physician-reported toxicities. This study reported that 40 patients treated with IMPT had decreased dose to multiple OARs and less deterioration in the following PROs: pain, swallowing function, dry mouth, sticky saliva, sensory change, cough, speech, feeling ill, and social eating. Physician-reported toxicities demonstrated less oral pain. The authors suggested a strong consideration for IMPT in ipsilateral head and neck patients with cancer is warranted.